FierceBiotech 5 mars 2026 Alltrna undergoes third layoff round before entering clinic, cutting 35% of jobs
FierceBiotech 5 mars 2026 Daiichi Sankyo pens pact with Germany's Gaia to sell digital therapeutic for high cholesterol
FierceBiotech 4 mars 2026 Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'
FierceBiotech 4 mars 2026 Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
FierceBiotech 4 mars 2026 Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option
FierceBiotech 4 mars 2026 Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset
FierceBiotech 3 mars 2026 New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
FierceBiotech 3 mars 2026 Theravance halves headcount, ends all R&D work after phase 3 rare disease fail